Macrolide antibiotics for cystic fibrosis

Weight Gain and Obesity in Infants and Young Children Exposed to Prolonged Antibiotic Prophylaxis

“…A ntimicrobial agents can promote weight gain in young animals being raised for market consumption 1,2 and increase adiposity in young mice. 3 Similar effects have been observed in clinical trials carried out in children with cystic fibrosis 4 or human immunodeficiency virus infection 5 and in underweight children in developing countries. 6 Whether antibiotic use is a cause of excessive weight gain or obesity in healthy infants and young children is debated, and available evidence is limited to observational studies that have retrospectively evaluated growth effects in relation to incidental antibiotic exposures.…”

Weight Gain and Obesity in Infants and Young Children Exposed to Prolonged Antibiotic Prophylaxis

“…A ntimicrobial agents can promote weight gain in young animals being raised for market consumption 1,2 and increase adiposity in young mice. 3 Similar effects have been observed in clinical trials carried out in children with cystic fibrosis 4 or human immunodeficiency virus infection 5 and in underweight children in developing countries. 6 Whether antibiotic use is a cause of excessive weight gain or obesity in healthy infants and young children is debated, and available evidence is limited to observational studies that have retrospectively evaluated growth effects in relation to incidental antibiotic exposures.…”

Treatment of mucosa associated lymphoid tissue lymphoma with a long‐term once‐weekly regimen of oral azithromycin: Results from the phase II MALT—A trial

“…Tolerance of treatment was excellent, with the most common side effects being mild nausea in 8 and diarrhea in 4 patients each (see Table ) comparable with similar long‐term high‐dose regimes used in cystic fibrosis patients …”

Aerosolized Antibiotics for Patients with Bronchiectasis

“…Although the patients in the clinical trials are similar to our overall population in terms of number of exacerbations, there are striking differences from the treated group; notably, 40% of the patients in the clinical trials had no exacerbations in the previous year compared with only 3% of our study cohort. The patients in the clinical trials had a higher incidence of chronic obstructive pulmonary disease compared with our study cohort; there was a high rate of chronic obstructive pulmonary disease medications, but low rates of chronic macrolides and hypertonic saline, which are frequently used for the treatment of NCFB (11,12) and are much lower than used in our study cohort. Hence we suspect that the negative outcome of this particular trial may have been a result of the incorrect inclusion of subjects.…”

Weight Gain and Obesity in Infants and Young Children Exposed to Prolonged Antibiotic Prophylaxis

“…A ntimicrobial agents can promote weight gain in young animals being raised for market consumption 1,2 and increase adiposity in young mice. 3 Similar effects have been observed in clinical trials carried out in children with cystic fibrosis 4 or human immunodeficiency virus infection 5 and in underweight children in developing countries. 6 Whether antibiotic use is a cause of excessive weight gain or obesity in healthy infants and young children is debated, and available evidence is limited to observational studies that have retrospectively evaluated growth effects in relation to incidental antibiotic exposures.…”

Treatment of mucosa associated lymphoid tissue lymphoma with a long‐term once‐weekly regimen of oral azithromycin: Results from the phase II MALT—A trial

“…Tolerance of treatment was excellent, with the most common side effects being mild nausea in 8 and diarrhea in 4 patients each (see Table ) comparable with similar long‐term high‐dose regimes used in cystic fibrosis patients …”

Aerosolized Antibiotics for Patients with Bronchiectasis

“…Although the patients in the clinical trials are similar to our overall population in terms of number of exacerbations, there are striking differences from the treated group; notably, 40% of the patients in the clinical trials had no exacerbations in the previous year compared with only 3% of our study cohort. The patients in the clinical trials had a higher incidence of chronic obstructive pulmonary disease compared with our study cohort; there was a high rate of chronic obstructive pulmonary disease medications, but low rates of chronic macrolides and hypertonic saline, which are frequently used for the treatment of NCFB (11,12) and are much lower than used in our study cohort. Hence we suspect that the negative outcome of this particular trial may have been a result of the incorrect inclusion of subjects.…”

Weight Gain and Obesity in Infants and Young Children Exposed to Prolonged Antibiotic Prophylaxis

“…A ntimicrobial agents can promote weight gain in young animals being raised for market consumption 1,2 and increase adiposity in young mice. 3 Similar effects have been observed in clinical trials carried out in children with cystic fibrosis 4 or human immunodeficiency virus infection 5 and in underweight children in developing countries. 6 Whether antibiotic use is a cause of excessive weight gain or obesity in healthy infants and young children is debated, and available evidence is limited to observational studies that have retrospectively evaluated growth effects in relation to incidental antibiotic exposures.…”

Treatment of mucosa associated lymphoid tissue lymphoma with a long‐term once‐weekly regimen of oral azithromycin: Results from the phase II MALT—A trial

“…Tolerance of treatment was excellent, with the most common side effects being mild nausea in 8 and diarrhea in 4 patients each (see Table ) comparable with similar long‐term high‐dose regimes used in cystic fibrosis patients …”

Aerosolized Antibiotics for Patients with Bronchiectasis

“…Although the patients in the clinical trials are similar to our overall population in terms of number of exacerbations, there are striking differences from the treated group; notably, 40% of the patients in the clinical trials had no exacerbations in the previous year compared with only 3% of our study cohort. The patients in the clinical trials had a higher incidence of chronic obstructive pulmonary disease compared with our study cohort; there was a high rate of chronic obstructive pulmonary disease medications, but low rates of chronic macrolides and hypertonic saline, which are frequently used for the treatment of NCFB (11,12) and are much lower than used in our study cohort. Hence we suspect that the negative outcome of this particular trial may have been a result of the incorrect inclusion of subjects.…”